ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis
- 42 Downloads
Dr. Kurzrock has received research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, and Guardant Health; consultant fees from Sequenom, Loxo and Actuate Therapeutics; and speaker fees from Roche. He also has an ownership interest in Curematch, Inc. Drs. Baumgartner has no relevant disclosures.